Vaginal Dryness After Menopause

The vulva is the external genital area; the vagina is the internal canal. Dryness or irritation can affect either. You may notice itching, burning, reduced lubrication, soreness with clothing or movement, or discomfort during penetration. Some people also have urgency, frequent urination, or recurrent urinary infections.

The term genitourinary syndrome of menopause, or GSM, describes menopause-related genital, sexual, and urinary symptoms. A clinician can assess whether the pattern fits and check for other causes. Unusual discharge, a persistent skin change, or pain should not simply be treated repeatedly as dryness without an assessment.

Use products intended for vaginal use and follow their instructions. Avoid perfumed soaps, washes, and douches if they irritate the area. An ordinary skin cream may be unsuitable internally. If a product stings or worsens symptoms, stop it and ask a pharmacist or clinician for advice.

Lubrication can reduce friction, but persistent pain needs investigation and treatment. Tell the clinician where it hurts and whether the pain occurs at entry, deeper inside, or afterward. You do not need to continue painful activity while waiting for care.

NICE recommends vaginal estrogen for menopause-related genitourinary symptoms, including for people using systemic HRT. Creams, tablets, inserts, or rings may be available depending on the country and product. Symptoms and preferences guide the formulation. Local treatment does not provide systemic treatment for hot flashes.

The current Vagifem US label, for example, uses a 10 microgram insert daily for two weeks, then twice weekly. Other products differ, so follow the schedule supplied with your prescription. Ask when improvement should be reviewed and whether continuing treatment is appropriate.

Low-dose vaginal treatment involves much less systemic exposure than systemic HRT, but medical history still matters. Tell the clinician about unexplained bleeding, hormone-sensitive cancer, and current cancer treatment. The vaginal-estrogen guide explains formulations and precautions in more detail.

ACOG recommends nonhormonal approaches first for people with a history of estrogen-dependent breast cancer. If symptoms remain troublesome, low-dose vaginal estrogen may be considered after discussing benefits and risks. For people taking an aromatase inhibitor, the decision should involve the patient, gynecologist, and oncologist.

This differs from assuming that every local product is either automatically safe or permanently excluded. Bring the cancer-treatment details and what you have already tried. The team should explain the evidence limits and agree on symptom review.

Any vaginal bleeding after twelve months without periods needs assessment, including spotting after sex or a small pink or brown discharge. Dry tissue can bleed, but that possibility does not rule out another cause. Arrange an appointment to have the bleeding investigated.

Pain or burning when urinating, urgency, and lower abdominal discomfort can indicate a bladder infection. Fever, chills, nausea, vomiting, or back or side pain may indicate a kidney infection and requires prompt care. Recurrent urinary symptoms need review even when menopause-related tissue changes are present.

If usual treatment does not help, the clinician can reassess skin conditions, pelvic-floor pain, infection, and other causes. NICE recommends vaginal laser treatment only as part of a randomized controlled trial. Ask about established options and the evidence before paying for a procedure.